Insider trade

Context Therapeutics (CNTX): CEO bought ~$70K

Martin A. Lehr, CEO at Context Therapeutics, bought ~$70K of Context Therapeutics shares.

~$70K
Approx. value · 100K sh @ $0.7008
920K
Holds after · shares reported
Traded
Jun 9, 2025
Filed
Jun 10, 2025

What stands out in this filing

  • The purchase added 12.2% to the shares this insider held before it; the filing reports 920,190 shares, held indirectly afterwards.
  • 100,000 shares at an average of $0.7008 each, as reported on the form.
  • 2 other insiders at CNTX also bought in the open market within 30 days.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 6, 2025Insider · 2 peopleInsiders: 2 purchases (~$37K)
  2. Jun 9, 2025 · this disclosureInsiderCEO purchased ~$70K of CNTX shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Context Therapeutics

OQRO holds no insider, Congress, fund or contract record for Context Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CNTX page.

How this filing works

Explore the data

Common questions

Which Context Therapeutics (CNTX) insider traded, and how much?

Martin A. Lehr, CEO at Context Therapeutics, bought ~$70K of Context Therapeutics shares. 100K shares at $0.70, open market.

When did it happen, and when was it made public?

Traded: Jun 9, 2025. Filed: Jun 10, 2025. That is 1 day between the two dates.

What stands out in this filing?

The purchase added 12.2% to the shares this insider held before it; the filing reports 920,190 shares, held indirectly afterwards. 100,000 shares at an average of $0.7008 each, as reported on the form. 2 other insiders at CNTX also bought in the open market within 30 days.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean CNTX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Context Therapeutics

Everything OQRO holds on this company is on its CNTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data